These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 11793469)

  • 1. Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms.
    Yuan ZQ; Gottlieb B; Beitel LK; Wong N; Gordon PH; Wang Q; Puisieux A; Foulkes WD; Trifiro M
    Hum Mutat; 2002 Feb; 19(2):108-13. PubMed ID: 11793469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of MLH1 mutations linked to hereditary nonpolyposis colon cancer.
    Nyström-Lahti M; Perrera C; Räschle M; Panyushkina-Seiler E; Marra G; Curci A; Quaresima B; Costanzo F; D'Urso M; Venuta S; Jiricny J
    Genes Chromosomes Cancer; 2002 Feb; 33(2):160-7. PubMed ID: 11793442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC).
    van der Klift H; Wijnen J; Wagner A; Verkuilen P; Tops C; Otway R; Kohonen-Corish M; Vasen H; Oliani C; Barana D; Moller P; Delozier-Blanchet C; Hutter P; Foulkes W; Lynch H; Burn J; Möslein G; Fodde R
    Genes Chromosomes Cancer; 2005 Oct; 44(2):123-38. PubMed ID: 15942939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
    Hendriks YM; Jagmohan-Changur S; van der Klift HM; Morreau H; van Puijenbroek M; Tops C; van Os T; Wagner A; Ausems MG; Gomez E; Breuning MH; Bröcker-Vriends AH; Vasen HF; Wijnen JT
    Gastroenterology; 2006 Feb; 130(2):312-22. PubMed ID: 16472587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel.
    Shia J; Tang LH; Vakiani E; Guillem JG; Stadler ZK; Soslow RA; Katabi N; Weiser MR; Paty PB; Temple LK; Nash GM; Wong WD; Offit K; Klimstra DS
    Am J Surg Pathol; 2009 Nov; 33(11):1639-45. PubMed ID: 19701074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
    Malander S; Rambech E; Kristoffersson U; Halvarsson B; Ridderheim M; Borg A; Nilbert M
    Gynecol Oncol; 2006 May; 101(2):238-43. PubMed ID: 16360201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features.
    Belvederesi L; Bianchi F; Loretelli C; Gagliardini D; Galizia E; Bracci R; Rosati S; Bearzi I; Viel A; Cellerino R; Porfiri E
    Eur J Hum Genet; 2006 Jul; 14(7):853-9. PubMed ID: 16724012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome.
    Carneiro da Silva F; Ferreira JR; Torrezan GT; Figueiredo MC; Santos ÉM; Nakagawa WT; Brianese RC; Petrolini de Oliveira L; Begnani MD; Aguiar-Junior S; Rossi BM; Ferreira Fde O; Carraro DM
    PLoS One; 2015; 10(10):e0139753. PubMed ID: 26437257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.
    Halvarsson B; Lindblom A; Rambech E; Lagerstedt K; Nilbert M
    Fam Cancer; 2006; 5(4):353-8. PubMed ID: 16817031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human MutL homolog (MLH1) function in DNA mismatch repair: a prospective screen for missense mutations in the ATPase domain.
    Ellison AR; Lofing J; Bitter GA
    Nucleic Acids Res; 2004; 32(18):5321-38. PubMed ID: 15475387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.
    Andersen SD; Liberti SE; Lützen A; Drost M; Bernstein I; Nilbert M; Dominguez M; Nyström M; Hansen TV; Christoffersen JW; Jäger AC; de Wind N; Nielsen FC; Tørring PM; Rasmussen LJ
    Hum Mutat; 2012 Dec; 33(12):1647-55. PubMed ID: 22753075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
    Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
    Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.
    Pistorius S; Görgens H; Plaschke J; Hoehl R; Krüger S; Engel C; Saeger HD; Schackert HK
    Cancer Lett; 2007 Apr; 248(1):89-95. PubMed ID: 16837128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary nonpolyposis colorectal cancer.
    Montazer Haghighi M; Radpour R; Aghajani K; Zali N; Molaei M; Zali MR
    Int J Colorectal Dis; 2009 Aug; 24(8):885-93. PubMed ID: 19479271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic investigation of DNA-repair pathway genes PMS2, MLH1, MSH2, MSH6, MUTYH, OGG1 and MTH1 in sporadic colon cancer.
    Schafmayer C; Buch S; Egberts JH; Franke A; Brosch M; El Sharawy A; Conring M; Koschnick M; Schwiedernoch S; Katalinic A; Kremer B; Fölsch UR; Krawczak M; Fändrich F; Schreiber S; Tepel J; Hampe J
    Int J Cancer; 2007 Aug; 121(3):555-8. PubMed ID: 17417778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
    Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
    J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer.
    Truninger K; Menigatti M; Luz J; Russell A; Haider R; Gebbers JO; Bannwart F; Yurtsever H; Neuweiler J; Riehle HM; Cattaruzza MS; Heinimann K; Schär P; Jiricny J; Marra G
    Gastroenterology; 2005 May; 128(5):1160-71. PubMed ID: 15887099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PMS2 involvement in patients suspected of Lynch syndrome.
    Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
    Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse.
    Chen PC; Dudley S; Hagen W; Dizon D; Paxton L; Reichow D; Yoon SR; Yang K; Arnheim N; Liskay RM; Lipkin SM
    Cancer Res; 2005 Oct; 65(19):8662-70. PubMed ID: 16204034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.